12(S)-HEPE
Based on 1 Customer Validation
12 (S)-HEPE is an oxidation product of Eicosapentaenoic acid (HY-B0660). 12 (S)-HEPE activates p38α, GSKβ, CREB, and ERK1/2. 12 (S)-HEPE induces DNA synthesis. 12 (S)-HEPE leads to activation of the PI3K-mTORC2-Akt signaling pathway and translocation of Glut4 to the plasma membrane. 12 (S)-HEPE increases glucose uptake. 12 (S)-HEPE reduces body weight gain in HFD mice. 12 (S)-HEPE can be used in research on colorectal cancer, zymosan-induced peritonitis, diabetes, and obesity.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.9%
- CAS. Nr.: 116180-17-7
- Formel: C₂₀H₃₀O₃
- Molecular Weight:318.45
-
Speicherung:
Solution, -20°C, 2 years
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-113490
15-KETE -
HY-150084
(±)14,15-Epoxyeicosatrienoic acidProliferation Inducer -
HY-130675A
15(S)-HEPEAsthma Marker -
HY-113434
5(S)-HETEEndogenous Metabolite -
HY-130060
12(S)-HETrEPlatelet Aggregation Inhibitor -
HY-130309
(±)8(9)-EpETEEpoxide -
HY-124404A
12(S)-HETEP38 MAPK/ERK Activator -
HY-120954
14,15-EE-5(Z)-E14,15-EET structural analogue -
HY-130140
8,9-DiHETEEster Product -
HY-118332
19(R)-HETEVasodilator -
HY-130138C
5,6-DiHETEAnti-inflammatory Lipid Mediators -
HY-113711
15-OxoEDEEster Product
Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
ERK1 |
ERK2 |
p38α |
mTORC2 |
GLUT4 |
In Vitro
12 (S)-HEPE (100-1000 nM; 48 h) induces Caco-2 cell growth and DNA synthesis, and this effect is blocked by COX and BLT antagonists[1].
12 (S)-HEPE (100 nM; 5-15 min) activates phosphorylation of p38α, GSKβ, CREB, and ERK1/2 in Caco-2 cells, but does not activate AKT1 or AKT2[1].
12 (S)-HEPE (0.01-1 μM; 30 min) increases glucose uptake in WT-1 mouse brown adipocytes through a Gs/PI3K/mTORC2-dependent pathway[3].
12 (S)-HEPE (0.01-1 μM; 30 min) increases glucose uptake in differentiated C2C12 myotubes[3].
12 (S)-HEPE (5-45 min) activates the Akt/mTORC2/AS160 signaling pathway in WT-1 mouse brown adipocytes[3].
12 (S)-HEPE supports the formation of receptor-G protein complexes in primary hepatocyte plasma membrane fractions, thereby enabling the identification of 8 candidate proteins[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human intestinal Caco-2 cells
-
Concentration:10, 100, 1000 nM; 100 nM plus U75302 5 μM, LY255283 25 μM, or ketoprofen 5 μM
-
Incubation Time:48 h
-
Result:Induced significant cell growth and DNA synthesis at 100 and 1000 nM.
This mitogenic action was blocked by ketoprofen (COX inhibitor), U75302 (BLT1 antagonist), and LY255283 (BLT1/BLT2 antagonist).
-
Cell Line:human intestinal Caco-2 cells
-
Concentration:100 nM
-
Incubation Time:5 or 15 min
-
Result:O.D. 450 nm values for 12(S)-HEPE were AKT1 0.19; AKT2 0.21; p38α 0.85; GSKβ 0.48; CREB 0.76; ERK1/2 0.95.
Increased phosphorylation of p38α, GSKβ, CREB, and ERK1/2, with no effect on AKT1 or AKT2.
In Vivo
12(S)-HEPE (200 µg/kg; intravenous injection; single dose) acutely increases glucose uptake in BAT and skeletal muscle of lean mice[3].
12(S)-HEPE (8 weeks) reduces body weight gain and improves glucose and insulin tolerance in HFD-fed wild-type mice, but has no such effect in Olfr110-/- mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 6 weeks old at start of high-fat diet; diet-induced obese after 16 weeks of high-fat diet)[3]
-
Dosage:200 μg/kg body weight
-
Administration:i.p.; once daily; for 2 weeks
-
Result:Circulating 12-HEPE levels increased 2.5-fold 30 min after i.p. administration.
No change in body weight gain or fasting glucose.
12(S)-HEPE-treated DIO mice showed improved glucose tolerance and improved insulin sensitivity compared with vehicle-treated mice.
No difference in serum insulin before or after glucose injection.
No change in food intake, physical activity, VCO2, or VO2.
BAT weight was increased.
BAT mRNA expression of Glut-1, Chrebp-b, and Fasn was increased.
IL-10 expression was increased in pgWAT; no differences in M1/M2 macrophage populations in pgWAT.
-
Animal Model:C57BL/6J (male, 12 weeks old)[3]
-
Dosage:200 µg/kg
-
Administration:retro-orbital (i.v.); single dose
-
Result:Significantly increased [3H]2-deoxyglucose uptake into BAT and skeletal muscle but not into pgWAT, ingWAT, or liver.
Chemical Information
-
CAS. Nr. 116180-17-7
-
Appearance Liquid
-
Molecular Weight 318.45
-
Formel C₂₀H₃₀O₃
-
Color Colorless to light yellow
-
SMILES
CC/C=C\C/C=C\C[C@H](O)/C=C/C=C\C/C=C\CCCC(O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Solution, -20°C, 2 years
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
12(S)-HEPE Related Classifications
HY-W747548 Related Classifications
Powered by Bioz